Serveur d'exploration Tocilizumab - Analysis (2020)

Index « AbsEn.i » - entrée « effectiveness »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
effectively < effectiveness < effector  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 24.
[0-20] [0 - 20][0 - 24][20-23][20-40]
Ident.Authors (with country if any)Title
000006 (2020) Anna Jakubczyc ; Claus Neurohr[Interstitial lung disease in rheumatic diseases - new therapeutic approaches].
000014 (2020) Puja Mehta ; Jessica J. MansonWhat Is the Clinical Relevance of TNF Inhibitor Immunogenicity in the Management of Patients With Rheumatoid Arthritis?
000063 (2020) Mitsuhiro Akiyama [Japon] ; Yuko Kaneko [Japon] ; Tsutomu Takeuchi [Japon]Tocilizumab in isolated polymyalgia rheumatica: A systematic literature review.
000122 (2020) Timothy M. Smith ; Anuj Tharakan ; Rebecca K. MartinTargeting ADAM10 in Cancer and Autoimmunity
000139 (2020) Chayma Ladhari [France] ; Pierre Le Blay [France] ; Thierry Vincent [France] ; Ahmed Larbi [France] ; Emma Rubenstein [France] ; Rosanna Ferreira Lopez [France] ; Christian Jorgensen [France] ; Yves-Marie Pers [France]Successful long-term remission through tapering tocilizumab infusions: a single-center prospective study
000168 (2020) Tsutomu Takeuchi [Japon] ; Yoshiya Tanaka [Japon] ; Sakae Tanaka [Japon] ; Atsushi Kawakami [Japon] ; Yeong-Wook Song [Corée du Sud] ; Yi-Hsing Chen [Taïwan] ; Mitsuhiro Rokuda [Japon] ; Hiroyuki Izutsu [Japon] ; Satoshi Ushijima [Japon] ; Yuichiro Kaneko [Japon] ; Yoshihiro Nakashima [Japon] ; Teruaki Shiomi [Japon] ; Emi Yamada [Japon]Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan
000218 (2020) Piero Ruscitti [Italie] ; Paola Cipriani [Italie] ; Vasiliki Liakouli [Italie] ; Daniela Iacono [Italie] ; Ilenia Pantano [Italie] ; Francesco Caso [Italie] ; Federico Perosa [Italie] ; Fabiola Atzeni [Italie] ; Francesco Paolo Cantatore [Italie] ; Raffaele Scarpa [Italie] ; Francesco Ciccia [Italie] ; Roberto Giacomelli [Italie]Prescribing motivations and patients' characteristics related to the use of biologic drugs in adult-onset Still's disease: analysis of a multicentre "real-life" cohort.
000292 (2020) Fujun Peng [République populaire de Chine] ; Lei Tu [République populaire de Chine] ; Yongshi Yang [République populaire de Chine] ; Peng Hu [République populaire de Chine] ; Runsheng Wang [République populaire de Chine] ; Qinyong Hu [République populaire de Chine] ; Feng Cao [République populaire de Chine] ; Taijiao Jiang [République populaire de Chine] ; Jinlyu Sun [République populaire de Chine] ; Guogang Xu [République populaire de Chine] ; Christopher Chang [États-Unis]Management and Treatment of COVID-19: The Chinese Experience
000348 (2020) Sisi Xie ; Shu Li ; Jing Tian ; Fen LiIguratimod as a New Drug for Rheumatoid Arthritis: Current Landscape
000361 (2020) Kunihiko Umekita ; Akihiko OkayamaHTLV-1 Infection and Rheumatic Diseases
000385 (2020) Gaëlle Vial [France] ; Anaïs De Pouilly [France] ; Laetitia Scouppe [France] ; Bruno Pereira [France] ; Claire Daien [France] ; Cédric Lukas [France] ; Adeline Ruyssen-Witrand [France] ; Pascale Vergne-Salle [France] ; Christophe Richez [France] ; Anne Tournadre [France]Factors influencing the choice of biologic therapy following Rituximab in patients with rheumatoid arthritis: A retrospective study using propensity score.
000396 (2020) Patricia Ruiz-Limon [Espagne] ; Maria Lourdes Ladehesa-Pineda [Espagne] ; Maria Del Carmen Castro-Villegas [Espagne] ; Maria Del Carmen Abalos-Aguilera [Espagne] ; Clementina Lopez-Medina [Espagne] ; Chary Lopez-Pedrera [Espagne] ; Nuria Barbarroja [Espagne] ; Daniel Espejo-Peralbo [Espagne] ; Jose Antonio Gonzalez-Reyes [Espagne] ; Jose Manuel Villalba [Espagne] ; Carlos Perez-Sanchez [Espagne] ; Alejandro Escudero-Contreras [Espagne] ; Eduardo Collantes-Estevez [Espagne] ; Pilar Font-Ugalde [Espagne] ; Yolanda Jimenez-Gomez [Espagne]Enhanced NETosis generation in radiographic axial spondyloarthritis: utility as biomarker for disease activity and anti-TNF-α therapy effectiveness
000412 (2020) Sathana Ingaralingam [Royaume-Uni] ; Saaeha Rauz [Royaume-Uni] ; Philip I. Murray [Royaume-Uni] ; Robert J. Barry [Royaume-Uni]Effectiveness of pharmacological agents for the treatment of non-infectious scleritis: a systematic review protocol
000413 (2020) Mauricio Cordero-Alfaro [Costa Rica] ; Carlos Le N-Céspedes [Costa Rica] ; Allan Ramos-Esquivel [Costa Rica]Effectiveness of intravenous tocilizumab in routine clinical practice in a cohort of Costa Rican patients with rheumatoid arthritis.
000414 (2020) Guiomar Pinheiro [Portugal] ; Ana Rita Costa [Portugal] ; Ana Campar [Portugal] ; Teresa Mendonça [Portugal]Effectiveness of Tocilizumab in the Treatment of Fasciitis with Eosinophilia: Two Case Reports
000415 (2020) Tomoyuki Asano ; Shuzo Sato ; Jumpei Temmoku ; Yuya Fujita ; Makiko Yashiro Furuya ; Naoki Matsuoka ; Hiroko Kobayashi ; Eiji Suzuki [Japon] ; Hiroshi Watanabe ; Kiyoshi MigitaEffectiveness of Tocilizumab in juvenile patients with refractory Takayasu arteritis
000416 (2020) Dimitrios A. Pappas [États-Unis] ; Carol J. Etzel [États-Unis] ; Margaux Crabtree [États-Unis] ; Taylor Blachley [États-Unis] ; Jennie Best [États-Unis] ; Steve Zlotnick [États-Unis] ; Joel M. Kremer [États-Unis]Effectiveness of Tocilizumab in Patients With Rheumatoid Arthritis is Unaffected by Comorbidity Burden or Obesity: Data From a US Registry.
000417 (2020) Matthijs S. Van Der Leeuw [Pays-Bas] ; Paco M. J. Welsing [Pays-Bas] ; Maria J. H. De Hair [Pays-Bas] ; Johannes W. G. Jacobs [Pays-Bas] ; Anne C. A. Marijnissen [Pays-Bas] ; Suzanne P. Linn-Rasker [Pays-Bas] ; Faouzia Fodili [Pays-Bas] ; Reinhard Bos [Pays-Bas] ; Janneke Tekstra [Pays-Bas] ; Jacob M. Van Laar [Pays-Bas]Effectiveness of TOcilizumab in comparison to Prednisone In Rheumatoid Arthritis patients with insufficient response to disease-modifying antirheumatic drugs (TOPIRA): study protocol for a pragmatic trial
000418 (2020) Martin Michaud [France] ; Olivier Lidove [France] ; Boris Bienvenu [France] ; Laurent Chiche [France] ; Geoffrey Urbanski [France]Effectiveness and tolerance of off-label use of tocilizumab in autoimmune diseases: A Multicenter Study.
000460 (2020) Celine J. Van De Laar ; Martijn A H. Oude Voshaar ; Walid K H. Fakhouri [États-Unis] ; Liliana Zaremba-Pechmann [États-Unis] ; Francesco De Leonardis [États-Unis] ; Inmaculada De La Torre [États-Unis] ; Mart A F J. Van De LaarCost-Effectiveness of a JAK1/JAK2 Inhibitor vs a Biologic Disease-Modifying Antirheumatic Drug (bDMARD) in a Treat-to-Target Strategy for Rheumatoid Arthritis
000485 (2020) Kim Lauper [Suisse] ; Denis Mongin [Suisse] ; Florenzo Iannone [Italie] ; Eirik K. Kristianslund [Norvège] ; Tore K. Kvien [Norvège] ; Dan C. Nordström [Finlande] ; Karel Pavelka [République tchèque] ; Manuel Pombo-Suarez [Espagne] ; Ziga Rotar [Slovénie] ; Maria J. Santos [Portugal] ; Catalin Codreanu [Roumanie] ; Galina Lukina [Russie] ; Sara L. Gale [États-Unis] ; Markus John [Suisse] ; Yves Luder [Suisse] ; Delphine S. Courvoisier [Suisse] ; Cem Gabay [Suisse]Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritis.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/2020/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/AbsEn.i -k "effectiveness" 
HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/AbsEn.i  \
                -Sk "effectiveness" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    2020
   |étape=   Analysis
   |type=    indexItem
   |index=    AbsEn.i
   |clé=    effectiveness
}}

Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021